protein arginine methyltransferase 8Genealiases: HRMT1L3 · HRMT1L4
Q-omics provides the consensus-scored PRMT8 profile across patient tissues and cancer cell-line models. PRMT8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PRMT8 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PRMT8 RNA expression shows 15,445 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where PRMT8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRMT8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRMT8 survival associations across molecular data types. PRMT8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRMT8 RNA expression–survival associations across cancer types. High PRMT8 expression shows unfavorable associations in BLCA, DLBC, UVM and ACC, but favorable associations in LUAD and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PRMT8 RNA expression.
This table summarizes PRMT8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PRMT8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRMT8 shows lower tumor expression in KIRC, LUSC, KIRP and LUAD and higher tumor expression in THCA and HNSC. The KIRC box plot shows higher PRMT8 RNA expression in normal versus tumor tissue (log2 FC = −0.288, t-test p < 0.001).
This table shows molecular features associated with PRMT8 in patient tissues and cancer cell lines. In patient samples, PRMT8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRMT8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
